Toramat

Leaflet attached to the packaging: information for the user

Toramat, 25 mg, coated tablets

Toramat, 50 mg, coated tablets

Toramat, 100 mg, coated tablets

Toramat, 200 mg, coated tablets

Topiramate
This medicinal product is subject to additional monitoring. This will allow for quick identification of new safety information. The user of the medicinal product can also help by reporting any adverse reactions that occur after taking the medicinal product. To find out how to report adverse reactions, see section 4.

You should carefully read the contents of the leaflet before taking the medicinal product, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• If you have any doubts, you should consult a doctor or pharmacist.
• This medicinal product has been prescribed specifically for you. Do not pass it on to others. The medicinal product may harm another person, even if their symptoms are the same.
• If the patient experiences any adverse reactions, including any adverse reactions not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet:

• 1. What Toramat is and what it is used for
• 2. Important information before taking Toramat
• 3. How to take Toramat
• 4. Possible adverse reactions
• 5. How to store Toramat
• 6. Contents of the packaging and other information

1. What Toramat is and what it is used for

Toramat belongs to a group of medicines called antiepileptic medicines. It is used:

• as a single medicine for the treatment of epileptic seizures in adults and children over 6 years of age,
• in combination with other medicines for the treatment of epileptic seizures in adults and children over 2 years of age,
• for the prevention of migraine headaches in adults.

2. Important information before taking Toramat

When not to take Toramat

• if the patient is allergic to topiramate or any of the other ingredients of this medicinal product (listed in section 6).

Migraine prevention

• Toramat must not be taken during pregnancy.
• If the patient is of childbearing age, Toramat must not be taken without using highly effective contraception during treatment. See below in the section "Pregnancy, breastfeeding and fertility - important advice for women".

Epilepsy treatment

• Toramat must not be taken if the patient is pregnant, unless no other treatment method provides sufficient control of epileptic seizures.
• If the patient is of childbearing age, Toramat must not be taken without using highly effective contraception during treatment. The only exception is when Toramat is the only medicine that provides sufficient control of seizures, and the patient plans to become pregnant. The patient should discuss this with their doctor to ensure they have received information about the risk of taking Toramat during pregnancy and the risk of seizures during pregnancy, which may put the patient or the unborn child at risk.

It is essential to read the Patient Guide provided by the doctor or scan the QR code (see section 6 "Contents of the packaging and other information").
A patient card is attached to the packaging of Toramat, which reminds about the risk associated with pregnancy.
If the patient is unsure whether any of the above situations apply to them, they should consult their doctor or pharmacist before taking this medicinal product.

Warnings and precautions

Before starting to take this medicinal product, the patient should discuss it with their doctor or pharmacist if:

• the patient has kidney disease, especially kidney stones or is undergoing dialysis
• the patient has previously had blood and body fluid disorders (metabolic acidosis)
• the patient has liver disease
• the patient has eye diseases, especially glaucoma
• the patient has growth disorders
• the patient is on a high-fat diet (ketogenic diet)
• the patient is a woman of childbearing age. Toramat taken during pregnancy may harm the unborn child. During treatment and for at least 4 weeks after the last dose of Toramat, a highly effective method of contraception should be used. Further information can be found in the section "Pregnancy and breastfeeding".
• the patient is pregnant. Toramat taken during pregnancy may harm the unborn child.

If the patient is unsure whether any of the above situations apply to them, they should consult their doctor before taking this medicinal product.
If the patient has epilepsy, it is essential not to stop taking the medicinal product without consulting a doctor.
The patient should consult their doctor before taking any medicinal product containing topiramate that has been prescribed as a substitute for Toramat.
During treatment with Toramat, the patient may lose weight, so it is essential to regularly monitor body weight during treatment with this medicinal product. If the patient loses too much weight or if a child taking this medicinal product does not gain enough weight, they should consult their doctor.
In a small number of people taking antiepileptic medicines, such as Toramat, thoughts of self-harm or suicide have occurred. If such thoughts ever occur to the patient, they should contact their doctor immediately.
Toramat may cause severe skin reactions; if a rash and/or blisters appear on the skin, the patient should immediately inform their doctor (see also section 4 "Possible adverse reactions").
Toramat may rarely cause an increase in blood ammonia levels (detected in blood tests), which can cause changes in brain function, especially if the patient is also taking a medicinal product containing valproic acid or sodium valproate. Since this can be a severe condition, the patient should immediately tell their doctor if they experience any of the following adverse reactions (see also section 4 "Possible adverse reactions"):

• difficulty thinking, remembering, or solving problems,
• decreased alertness or awareness,
• feeling of strong drowsiness with lack of energy.

The risk of these symptoms may increase when taking high doses of Toramat.

Toramat and other medicines

The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Toramat may interact with other medicines. Therefore, it may sometimes be necessary to adjust the dose of the medicines taken by the patient or to change the dose of Toramat accordingly.
In particular, the patient should inform their doctor or pharmacist if they are taking:

• other medicines that have a harmful effect or decrease thinking, concentration, or muscle coordination (e.g., central nervous system depressants, such as muscle relaxants and sedatives),
• hormonal contraceptives. Toramat may decrease the effectiveness of hormonal contraceptives. The patient should use an additional barrier method of contraception, such as a condom or diaphragm/cervical cap. The patient should discuss with their doctor the best method of contraception to use while taking Toramat.

The patient should tell their doctor if their menstrual bleeding changes while taking hormonal contraceptives and Toramat. Irregular menstrual bleeding may occur. In such cases, the patient should continue to use hormonal contraceptives and inform their doctor.
The patient should keep a list of all medicines they are taking. When starting to take a new medicine, the patient should show this list to their doctor and pharmacist.
The patient should discuss with their doctor or pharmacist the use of other medicines, such as other antiepileptic medicines, risperidone, lithium, hydrochlorothiazide, metformin, pioglitazone, glibenclamide, amitriptyline, propranolol, diltiazem, venlafaxine, flunarizine, St. John's Wort (Hypericum perforatum) (a herbal preparation used to treat depression), warfarin used as an anticoagulant.
If the patient is unsure whether any of the above situations apply to them, they should consult their doctor or pharmacist before taking this medicinal product.

Taking Toramat with food and drink

Toramat can be taken with or without food. During treatment with Toramat, the patient should drink plenty of fluids throughout the day to prevent the formation of kidney stones. During treatment with Toramat, the patient should avoid consuming alcohol.

Pregnancy and breastfeeding

Important advice for women of childbearing age
Toramat may harm the unborn child. Women of childbearing age should discuss with their doctor the possibility of using other treatment methods instead of Toramat. If the decision is made to start treatment with Toramat, the patient should use highly effective contraception during treatment and for at least 4 weeks after the last dose of Toramat.
Migraine prevention

• Toramat must not be taken during pregnancy.
• Toramat must not be taken if the patient is of childbearing age unless a highly effective method of contraception is used.
• Before starting treatment with Toramat, a pregnancy test should be performed in women of childbearing age.

Epilepsy treatment

• Toramat must not be taken if the patient is pregnant unless no other treatment method provides sufficient control of epileptic seizures.
• Toramat must not be taken if the patient is of childbearing age unless a highly effective method of contraception is used. The only exception is when Toramat is the only medicine that provides sufficient control of seizures, and the patient plans to become pregnant. The patient should discuss this with their doctor to ensure they have received information about the risk of taking Toramat during pregnancy and the risk of seizures during pregnancy, which may put the patient or the unborn child at risk.
• Before starting treatment with Toramat, a pregnancy test should be performed in women of childbearing age.

Risk of taking topiramate during pregnancy (regardless of the disease being treated):
There is a risk of harmful effects on the unborn child if Toramat is taken during pregnancy.

• Taking Toramat during pregnancy increases the risk of birth defects in the child. In women taking topiramate, birth defects occur in about 4-9 out of 100 children. For comparison, this figure is 1-3 out of 100 children born to women who do not have epilepsy and do not take antiepileptic medicines. In particular, cleft lip (cleft lip) and cleft palate (cleft palate) have been observed. In newborn boys, a developmental defect of the penis (hypospadias) may also occur. These defects can develop early in pregnancy, even before the patient knows they are pregnant.
• Taking Toramat during pregnancy may increase the risk of autism spectrum disorders, intellectual disability, or attention deficit hyperactivity disorder (ADHD) in the child by 2 to 3 times compared to children born to women with epilepsy who do not take antiepileptic medicines.
• Taking Toramat during pregnancy may result in the child being smaller and having a lower birth weight. In one study, 18% of children whose mothers took topiramate during pregnancy were smaller and weighed less than expected, while in women without epilepsy who did not take antiepileptic medicines, this figure was 5% of newborns.
• In case of doubts, the patient should ask their doctor about the risk during pregnancy. Other medicines used to treat this disease may be available, which are associated with a lower risk of birth defects.

Necessity of using contraception in women of childbearing age:

• Women of childbearing age should discuss with their doctor the possibility of using other treatment methods instead of Toramat. If the decision is made to start treatment with Toramat, the patient should use highly effective contraception during treatment and for at least 4 weeks after the last dose of Toramat.
• The patient should use one highly effective contraceptive method (such as an intrauterine device) or two complementary methods of contraception, such as a contraceptive pill, in combination with a barrier method of contraception (such as a condom or diaphragm/cervical cap). The patient should discuss with their doctor which method of contraception will be most suitable for them.

If the patient is taking hormonal contraceptives, topiramate may decrease their effectiveness. Therefore, the patient should use an additional barrier method of contraception (such as a condom or diaphragm/cervical cap).

• If irregular menstrual bleeding occurs, the patient should inform their doctor.
• Taking Toramat in girls:The parents or guardians of a girl treated with Toramat must immediately contact the doctor when the girl experiences her first menstrual period. The doctor will inform them about the risk to the unborn child resulting from exposure to topiramate during pregnancy and the need to use highly effective contraception.

If the patient wants to become pregnant while taking Toramat:

• The patient should make an appointment with their doctor.
• The patient should not stop using contraception until they have discussed this with their doctor.
• If the patient is taking Toramat for epilepsy, they should not stop taking it without consulting their doctor, as the disease may worsen.
• The doctor will reassess the treatment and alternative treatment options. The doctor will inform the patient about the risk of taking Toramat during pregnancy and may refer them to another specialist.
• If the patient becomes pregnant or suspects they may be pregnant while taking Toramat:
• The patient should make an urgent appointment with their doctor.
• If the patient is taking Toramat for migraine prevention, they should stop taking it immediately and consult their doctor, who will assess whether alternative treatment is necessary.
• If the patient is taking Toramat for epilepsy, they should not stop taking it without consulting their doctor, as this may worsen the disease. Worsening of epilepsy may put the patient or the unborn child at risk.
• The doctor will reassess the treatment and alternative treatment options. The doctor will inform the patient about the risk of taking Toramat during pregnancy and may refer them to another specialist.
• If Toramat is taken during pregnancy, the patient will be closely monitored to check the development of the unborn child.

The patient should carefully read the Patient Guide provided by their doctor. The Patient Guide can also be obtained by scanning the QR code, see section 6 "Contents of the packaging and other information".
A patient card is attached to the packaging of Toramat, which reminds about the risk associated with taking topiramate during pregnancy.
Breastfeeding
The active substance of Toramat, topiramate, passes into breast milk. In children breastfed by mothers taking this medicinal product, adverse reactions such as diarrhea, drowsiness, irritability, and low weight gain have occurred. Therefore, the doctor will discuss with the patient whether to stop breastfeeding or stop taking Toramat. The doctor will consider the importance of the medicinal product for the mother and the risk to the child.
Mothers who are breastfeeding while taking Toramat must immediately inform their doctor if they notice any changes in their child's behavior.
Before taking any medicinal product, the patient should consult their doctor or pharmacist.

Driving and using machines

While taking Toramat, dizziness, fatigue, and vision disturbances may occur. The patient should not drive vehicles, use tools, or operate machines until they have consulted their doctor.

Toramat contains lactose monohydrate

If the patient has previously been diagnosed with intolerance to some sugars, they should contact their doctor before taking Toramat.
Toramat, 50 mg, coated tablets contain orange yellow S (E110), which may cause allergic reactions.
The bottles of Toramat contain a desiccant as a moisture-absorbing agent. The patient should not swallow the desiccant.

Other ingredients

This medicinal product contains less than 1 mmol of sodium (23 mg) per tablet, which means that the medicinal product is considered "sodium-free".

3. How to take Toramat

Toramat should always be taken as directed by the doctor. If the patient has any doubts, they should consult their doctor or pharmacist.
Girls and women of childbearing age:
Treatment with Toramat should be started and supervised by a doctor with experience in the treatment of epilepsy or migraines. The patient should visit their doctor at least once a year for treatment monitoring.

• The doctor usually recommends starting treatment with a low dose of Toramat and gradually increasing it until the appropriate dose for the patient is established.
• Toramat tablets should be swallowed whole. It is not recommended to chew the tablets, as they may leave a bitter taste.
• Toramat can be taken before, during, or after meals. During treatment with Toramat, the patient should drink plenty of fluids to prevent the formation of kidney stones.

Taking a higher dose of Toramat than recommended

• The patient should immediately contact their doctor. They should take the packaging of the medicinal product with them.
• The patient may experience drowsiness, fatigue, or decreased alertness, lack of coordination, difficulty speaking or concentrating, double vision or blurred vision, dizziness due to low blood pressure, feeling of depression or excitement, or abdominal pain or seizures.

Adverse reactions due to overdose may also occur when taking other medicines with Toramat.

Missing a dose of Toramat

• If a dose is missed, the patient should take it as soon as possible. However, if it is almost time for the next dose, the patient should skip the missed dose and continue treatment. If two or more doses are missed, the patient should contact their doctor.
• The patient should not take a double dose (two doses at the same time) to make up for the missed dose.

Stopping treatment with Toramat

The patient should not stop treatment unless their doctor has advised them to do so. After stopping treatment, the symptoms of the underlying disease may return. If the doctor decides to stop treatment, they will recommend gradually reducing the dose of Toramat over a few days.
If the patient has any further doubts about taking this medicinal product, they should consult their doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, Toramat can cause adverse reactions, although not everybody gets them.

If the following adverse reactions occur, the patient should immediately tell their doctor or seek medical attention:

Very common (may affect more than 1 in 10 people)

• Depression (onset or worsening of symptoms already present)

Common (may affect up to 1 in 10 people)

• Seizures (epileptic seizures)
• Anxiety, irritability, mood changes, confusion, disorientation
• Concentration disorders, slowed thinking, memory loss, memory disorders (new onset, sudden change, or worsening of symptoms)
• Kidney stones, frequent or painful urination

Uncommon (may affect up to 1 in 100 people)

• Metabolic acidosis (may cause breathing difficulties, including shortness of breath, loss of appetite, nausea, vomiting, excessive fatigue, and rapid or irregular heartbeat)
• Decreased or absent sweating (especially in young children if they are in a high-temperature environment)
• Thoughts of severe self-harm
• Loss of part of the visual field

Rare (may affect up to 1 in 1,000 people)

• Glaucoma - fluid accumulation in the eye chamber, causing increased pressure in the eye, pain, and impaired vision
• Difficulty thinking, remembering, or solving problems, decreased alertness or awareness, feeling of strong drowsiness with lack of energy - may be symptoms of high blood ammonia levels (hyperammonemia), which can cause changes in brain function (hyperammonemic encephalopathy).
• Severe skin reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis - may occur as a rash with blisters or without. Skin irritation, ulcers, or swelling in the mouth, throat, nose, eyes, and genital areas. Skin rashes can transform into severe, extensive skin damage (exfoliation and superficial mucosal damage), which can have life-threatening consequences.

Frequency not known (cannot be estimated from the available data):

• Eye inflammation (uveitis) with the following symptoms: eye redness, pain, sensitivity to light, tearing, blurred vision, or double vision.

Other adverse reactions that the patient should tell their doctor or pharmacist about if they worsen:

Very common (may affect more than 1 in 10 people)

• Nasal congestion, runny nose, or sore throat
• Numbness, pain, and/or tingling of various parts of the body
• Drowsiness, fatigue
• Dizziness
• Nausea, diarrhea
• Weight loss

Common (may affect up to 1 in 10 people)

• Anemia (reduced number of red blood cells)
• Allergic reactions (such as skin rash, redness, itching, swelling of the face, hives)
• Loss of appetite or decreased appetite
• Aggression, excitement, anger, abnormal behavior
• Difficulty falling asleep or waking up
• Difficulty speaking or speech disorders, slurred speech
• Clumsiness or lack of coordination, feeling of imbalance while walking
• Decreased ability to perform daily activities
• Decreased, lost, or altered sense of taste
• Involuntary trembling or seizures; rapid, uncontrolled eye movements
• Visual disturbances, such as double vision, blurred vision, impaired vision, problems with visual acuity
• Feeling of spinning (dizziness), ringing in the ears, ear pain
• Shortness of breath
• Cough
• Nosebleeds
• Fever, malaise, weakness
• Vomiting, constipation, abdominal pain or discomfort, nausea, gastrointestinal infections
• Dry mouth
• Hair loss
• Itching
• Joint pain or swelling, muscle cramps or spasms, muscle pain or weakness, chest pain
• Weight gain

Uncommon (may affect up to 1 in 100 people)

• Decreased platelet count (blood cells responsible for blood clotting), decreased white blood cell count, which helps protect the body against infection, decreased potassium levels in the blood
• Increased liver enzyme activity, increased eosinophil count in the blood (a type of white blood cell)
• Swollen lymph nodes in the neck, armpits, or groin
• Increased appetite
• Elevated mood
• Hearing, seeing, or feeling things that do not exist, severe mental disorders (psychoses)
• Inability to feel and express emotions, excessive suspiciousness, panic attacks
• Difficulty reading, speech disorders, difficulty with handwriting
• Restlessness, increased mental and physical activity
• Slowed thinking, decreased alertness
• Weak or slowed movements, involuntary, unusual, or repetitive muscle contractions
• Fainting/falls
• Abnormal or disturbed sense of touch; disturbed sense of touch
• Abnormal or disturbed sense of smell or its absence
• Unusual sensations or feelings that may precede the onset of migraine or certain types of seizures
• Dryness of the eye mucosa, increased sensitivity of the eyes to light, involuntary eyelid twitching, tearing
• Hearing loss, hearing loss in one ear
• Slow or irregular heartbeat, feeling of heartbeat in the chest
• Low blood pressure or decreased blood pressure when changing position to standing (which may cause a feeling of fainting, dizziness, or loss of consciousness in some people taking Toramat)
• Redness of the skin, hot flashes
• Pancreatitis
• Excessive gas, heartburn, feeling of fullness in the stomach or bloating
• Gum bleeding, excessive saliva production, drooling, bad breath
• Excessive fluid intake, thirst
• Skin discoloration
• Muscle stiffness, side pain
• Blood in the urine, incontinence, sudden urge to urinate, pain in the side or kidney area
• Sexual dysfunction, sexual disorders
• Flu-like symptoms
• Feeling of cold fingers and toes
• Feeling of intoxication
• Difficulty learning

Rare (may affect up to 1 in 1,000 people):

• Abnormal elevated mood
• Loss of consciousness
• Vision loss in one eye, transient blindness, night blindness
• Lazy eye syndrome
• Swelling of the tissues around the eyes
• Numbness, tingling, and color change (white, blue, and then red) of the fingers and toes after exposure to cold
• Hepatitis, liver function disorders
• Unpleasant body odor
• Unpleasant sensation in the hands and feet
• Kidney function disorders

Frequency not known (frequency cannot be estimated from the available data)

• Macular degeneration, yellow spot disease - the part of the eye responsible for sharp vision. If vision changes or vision impairment occur, the patient should contact their doctor

Children

Adverse reactions that occur in children are usually similar to those that occur in adults, but some adverse reactions may occur more frequently in children than in adults.

• Concentration problems
• Metabolic acidosis
• Thoughts of severe self-harm
• Fatigue
• Decreased or increased appetite
• Aggression, abnormal behavior
• Difficulty falling asleep or waking up
• Feeling of imbalance while walking
• Malaise
• Decreased potassium levels in the blood
• Lack of emotional expression
• Tearing
• Slow or irregular heartbeat

Other adverse reactions that may occur in children are:

Common (may affect up to 1 in 10 people)

• Feeling of spinning (dizziness)
• Vomiting
• Fever

Uncommon (may affect up to 1 in 100 people)

• Increased eosinophil count in the blood (a type of white blood cell)
• Hyperactivity
• Feeling of heat
• Difficulty learning

Reporting adverse reactions

If any adverse reactions occur, including any adverse reactions not listed in this leaflet, the patient should tell their doctor or pharmacist. Adverse reactions can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C, 02-222 Warsaw; tel.: +48 22 49 21 301; fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorization holder.
By reporting adverse reactions, more information can be collected on the safety of the medicinal product.

5. How to store Toramat

The medicinal product should be stored out of sight and reach of children.
Toramat should not be taken after the expiry date stated on the blister pack after EXP and on the carton or bottle after the expiry date (EXP). The expiry date refers to the last day of the month stated.
Plastic bottles
Do not store above 25°C.
Store the bottle tightly closed to protect from moisture.
Blister packs
Do not store above 25°C.
Store in the original packaging to protect from moisture.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Toramat contains

• The active substance of Toramat is topiramate (Topiramatum). Each coated tablet contains 25 mg, 50 mg, 100 mg, or 200 mg of topiramate.
• Other ingredients are:
• tablet core: lactose monohydrate, microcrystalline cellulose, maize starch, sodium carboxymethylcellulose (type A), magnesium stearate,
• tablet coating: hypromellose 5 cP, macrogol 400, polysorbate 80, titanium dioxide (E171).

Toramat, 50 mg, coated tablets also contain: orange yellow S (E110) and iron oxide yellow (E172).
Toramat, 100 mg and 200 mg, coated tablets also contain: iron oxide red (E172) and iron oxide yellow (E172).

What Toramat looks like and contents of the pack

Toramat, 25 mg, coated tablets are round, white, coated tablets with the letter "G" embossed on one side and the number "25" on the other side.
Toramat, 50 mg, coated tablets are round, yellow, coated tablets with the letter "G" embossed on one side and the number "50" on the other side.
Toramat, 100 mg, coated tablets are round, yellow, coated tablets with the letter "G" embossed on one side and the number "100" on the other side.
Toramat, 200 mg, coated tablets are round, pink, coated tablets with the letter "G" embossed on one side and the number "200" on the other side.
Toramat, 25 mg, 50 mg, 100 mg, and 200 mg, coated tablets are available in plastic bottles with a child-resistant closure and a screw cap, containing 28, 30, 56, 60 tablets, and a desiccant. The patient should not swallow the desiccant.
Toramat, 25 mg, 50 mg, 100 mg, and 200 mg, coated tablets are also available in blister packs of aluminum foil, containing 28, 30, 56, 60 tablets.
Not all pack sizes may be marketed.

Marketing authorization holder

neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert Str. 23
40764 Langenfeld
Germany

Manufacturer

Glenmark Pharmaceuticals Europe Limited
Building 2, Croxley Green Business Park
Croxley Green, Hertfordshire
WD18 8YA
United Kingdom
Glenmark Pharmaceuticals s.r.o.
Fibichova 143
566 17 Vysoké Mýto
Czech Republic

To obtain more detailed information about this medicinal product, the patient should contact the local representative of the marketing authorization holder:

Neuraxpharm Polska Sp. z o.o.
ul. Poleczki 35
02-822 Warsaw
info-poland@neuraxpharm.com
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Czech Republic: Topimark 25 mg, 50 mg, 100 mg film-coated tablets
Netherlands: Topiramaat Glenmark 25 mg, 50 mg, 100 mg, 200 mg film-coated tablets
Germany: Topiramat Glenmark 25 mg, 50 mg, 100 mg, 200 mg film-coated tablets
Poland: Toramat
Slovakia: Topimark 25 mg, 50 mg, 100 mg film-coated tablets

Date of last revision of the leaflet:

Other sources of information
The latest approved information (Patient Guide) about this medicinal product is available by scanning the following QR code with a smartphone.
This information is also available on the following website (URL):
https://rejestry.ezdrowie.gov.pl/rpl/search/public
After moving to the website, the patient should enter the name of the medicinal product and then open "Materials to download".